Tuesday 11th February, 2014 – (Lausanne, Switzerland). Today, Nestlé S.A. (Nestlé) announced the creation of Nestlé Skin Health S.A., a global leader focused on meeting the world’s increasing skin health needs with a scientifically-proven broad range of innovative products. The company will be formed by the acquisition of 50% of Galderma Pharma S.A. (Galderma), subject to regulatory clearance. Galderma was established in 1981 as a dermatology-focused, Swiss-based joint-venture between Nestlé and L’Oréal S.A. (L’Oréal) and had sales of CHF 2.0 billion in calendar year 2013.
Nestlé chairman Peter Brabeck-Letmathe said “Building on Nestlé’s historic strengths as a science based Nutrition, Health & Wellness Company and through the recent creation of Nestlé Health Science S.A., the company has reinforced its strategic direction to offer nutritional solutions from food & beverage to scientific products for a healthier life. By creating Nestlé Skin Health S.A. and by leveraging Galderma’s current portfolio, formulations and innovative research, Nestlé will now be able to provide science-based solutions for skin conditions. We strive to have a portfolio of innovative products that meet the full spectrum of people’s skin health needs over the course of their lives and to provide a holistic approach to people’s health.”
The establishment of Nestlé Skin Health will allow the emergence of a global leader that will leverage Galderma’s and Nestlé’s commercial operations throughout the world. Galderma’s Scientific Division, with laboratories located in France, Sweden, United States, Japan and Switzerland, will become part of Nestlé Skin Health and will actively collaborate with Nestlé’s global R&D network. Galderma’s 33 commercial subsidiaries around the world will continue to deliver scientifically-defined and medically-proven products to patients and healthcare providers around the world under the Galderma brand and organization.
Nestlé CEO Paul Bulcke said that “Nestlé Skin Health will have a broad commercial and R&D platform able to deliver state of the art solutions focused on maintaining, treating and restoring the health of the skin. The new company will be particularly effective working across different trade channels to help people meet their skin health needs at a time when access to medical care is getting more challenging due to resource constraints.” He added “Nestlé will contribute its Bübchen line of baby care products to Nestlé Skin Health and provide Galderma access to innovative technologies from Nestlé’s R&D as well to help develop Nestlé Skin Health’s future portfolio.”
Nestlé Skin Health will have a full range of products for the skin, hair and nail including self-medication drugs, quasi-drugs such as medicated soaps or sunscreens, therapeutic skin care products, nutraceuticals, prescription drugs and medical devices. Nestlé Skin Health, a wholly-owned subsidiary of Nestlé, will become operational as soon as regulatory requirements and competition authority clearance have been provided. Humberto C. Antunes, who currently serves as President and CEO of Galderma, will lead Nestlé Skin Health reporting to the company’s new Board of Directors. Peter Brabeck-Letmathe will become Chairman and Paul Bulcke Vice-chairman of the new Board of Directors of Nestlé Skin Health, based in Switzerland.
On behalf of Galderma, Humberto C. Antunes, CEO explained “this is good news for patients, consumers and healthcare providers, and the thousands of Galderma employees throughout the world. As part of Nestlé Skin Health, Galderma’s medical heritage and portfolio can be expanded to meet the full range of skin health needs, creating a new world leader focused on improving people’s lives.”
The skin, the largest organ in the human body, plays an important role in how we perceive ourselves and how others perceive us. Improving skin health has a proven impact on well-being and quality of life and these aspects, together with preventing, treating and curing medical conditions related to the skin, are what Nestlé Skin Health aspires to address.
About Nestlé Skin Health
Responding to increasing consumer needs, Nestlé will extend its activities to include the field of specialized, medical skin treatments through the creation of Nestlé Skin Health S.A., a global leader focused on meeting the world’s increasing skin health needs with a scientifically-proven broad range of innovative products. Nestlé Skin Health S.A. will be managed as a wholly-owned subsidiary of Nestlé S.A., with its own Board of Directors, located in Lausanne, Switzerland. Upon the approval and completion of Nestlé’s acquisition of the 50% stake of Galderma from L’Oréal, Galderma will form the foundation of Nestlé Skin Health S.A.
A global company exclusively dedicated to dermatology
Galderma is a global company founded in 1981 committed to delivering innovative medical solutions to meet the dermatological needs of people throughout their lifetime while serving healthcare professionals around the world. The company has 33 wholly-owned affiliates with a worldwide network of distributors and more than 5,000 employees. Galderma’s extensive product portfolio is available in 80 countries and treats a range of dermatological conditions including: acne, rosacea, onychomycosis, psoriasis & steroid-responsive dermatoses, pigmentary disorders, skin cancer and medical solutions for skin senescence.
With approximately 19% of revenues invested each year to discover and develop new products and access innovative technologies, the company is one of the world’s leading investors in dermatology R&D. Five state-of-the-art R&D centers and five manufacturing sites are dedicated to providing a wide range of innovative medical solutions which meet the highest standards of safety and efficacy.
Strategic brands include Epiduo, Oracea, Clobex, Differin, Mirvaso, Rozex/MetroGel, Silkis/Vectical, Tri-Luma, Loceryl, Cetaphil, Metvix, Azzalure, Restylane and Emervel.
For more information, please visit Galderma’s website www.galderma.com.
Public & Media Relations Officer
Phone: +41 79 722 6075
For any question, please contact email@example.com
Source: Galderma, http://www.galderma.com/News/articleType/ArticleView/articleId/56/Nestle-Skin-Health-Is-Created-Targeting-Global-Skin-Health-Needs
Dr. Palmer Taylor, a UC San Diego researcher whose work has helped advance understanding of communication between nerve cells, received France’s highest honor Thursday from an old friend and ongoing collaborator.
During a short ceremony at the Skaggs School of Pharmacy, Dr. Jean-Pierre Changeux pinned the French Legion of Honor medal to Taylor’s lapel.
“You have created and strengthened Franco-American connections and, more importantly, friendship between our two countries,” Changeux said.
A highly decorated neuroscientist who received his own Legion of Honor recognition in 2010, Changeux is a professor at Institut Pasteur and the Collège de France in Paris. Taylor has been the dean of the Skaggs School since it opened in 2002.
The Legion of Honor, established by Napoleon Bonaparte in 1802, rewards merit in soldiers and civilians. The medal comes in five degrees from Chevalier (knight) to Grand Croix (grand cross). Taylor received the chevalier order, which recognizes 20 or more years of exemplary public service.
About 10,000 Americans, including many World War I and II veterans, have received the Legion of Honor, which also recognizes achievements in fields ranging from arts and entertainment to sports. Seven San Diego County veterans also received the medal on Thursday at a ceremony in Chula Vista.
Taylor and Changeux have made significant contributions to their fields. Taylor is best known for his work in mapping the genetics of neurotransmitters, chemicals that carry signals across the synapses between nerve cells. Much of Changeux’s work has been in the discovery, and greater understanding, of certain nerve receptors which receive neurotransmitters and pass their signals into neurons.
The pair have been collaborating since 1995. The collaboration, Taylor said, has started with understanding the basic science of how these chemicals and structures operate, and has gradually grown to the point where there are several promising drugs now on the horizon.
“In the beginning of our time working together, we have been able to define the targets, how drugs interact with those targets and then refine the drugs so they are more specific,” Taylor said.
Several drugs that have been tested in animals have shown promise for enhancing brain activity in patients with cognition problems, from schizophrenia to Alzheimer’s disease, he said. Another class of potential new drugs also in testing, he said, could provide a better antidote for deadly nerve agents like the Sarin gas recently used in Syria.
“We are not only good friends, but we are also having a strong scientific and intellectual connection. We have chosen collaboration rather than competition, and it has been very productive,” Changeux said.
Taylor noted that famous musician Bob Dylan received the Legion of Honor last year. Dylan, he noted, was born less than 100 miles from his own home town in northern Wisconsin. There are other parallels, he added, between their interests.
“We both had interest in pharmacology, but it was done at different levels,” he said.
Source: UT San Diego, http://www.utsandiego.com/news/2014/feb/27/Taylor-Changeux-legion-honor/
Ardelyx licenses NaP2b phosphate inhibitor program for kidney disease to Sanofi in deal worth up to $198 million
FREMONT, CALIFORNIA. FEBRUARY 24, 2014 – Ardelyx, Inc. today announced that it has
licensed to Sanofi (NYSE: SNY; EURONEXT: SAN) its novel phosphate transport NaP2b
inhibitor program (also known as NaPi2b, Npt2b and SLC34A2). Ardelyx will receive an
undisclosed upfront payment from Sanofi. Total development and regulatory milestones could
potentially reach up to $198 million. Ardelyx would also be entitled to royalties on product sales.
In addition, Ardelyx retains an option to participate in co-promotional activities for the US
“Sanofi’s R&D and commercial capabilities in phosphate management are rivaled by no other
company, including their ability to test and understand our NaP2b inhibitor compounds in
relation to phosphate binders and other available phosphate management strategies,” stated Mike
Raab, CEO of Ardelyx.
Ardelyx’s NaP2b program includes a portfolio of minimally-absorbed NaP2b inhibitors in
discovery and preclinical stage of development, and Sanofi will have full responsibility for
further discovery efforts and development of any products. NaP2b is an intestinal phosphate
transporter whose activity accounts for a significant portion of dietary phosphate absorption in
humans. The inhibition of NaP2b should have utility for the treatment of hyperphosphatemia
(elevated serum phosphate) in patients with end stage renal disease (ESRD) and other forms of
chronic kidney disease (CKD).
Ardelyx, a venture-funded biopharmaceutical company, was founded on the design and
development of non- and minimally-absorbed, first-in-class oral therapeutics that target specific
gut transporters and receptors with drugs that address important medical issues in cardiorenal,
metabolic and gastrointestinal diseases. With this approach, Ardelyx has developed a pipeline of
drug candidates that act locally and specifically in the gastrointestinal (GI) tract, thereby limiting
the potential for systemic side effects, while impacting targets and pathways that modulate
The Company’s lead product, tenapanor, a minimally-absorbed, orally administered NHE3
sodium transport inhibitor, is being evaluated both for prevention of sodium and fluid overload
in patients with kidney and heart disease and for constipation-predominant irritable bowel
syndrome (IBS-C). Tenapanor is being developed by AstraZeneca under an exclusive license
from Ardelyx. Additionally, Ardelyx has other products in early development for cardiorenal,
metabolic and gastrointestinal diseases. To date, Ardelyx has raised $56 million in venture and
angel funding since it was founded in 2007, and has received $50 million in non-dilutive funding
from AstraZeneca. Ardelyx is located in Fremont, California.
For more information, visit Ardelyx’s website at www.ardelyx.com.
Media and Investors Contacts:
Mr. Mark Kaufmann
Chief Business Officer
Source: Ardelyx, http://www.ardelyx.com/wp-content/wbuploads/wb_news/Ardelyx%20NaP2b%20License%20Deal%20with%20Sanofi%20-%20Final(1).pdf
Source: BIOTECH FINANCES
Ecoutez l’interview sur le site de BIOTECH FINANCES >> listen here <<
(audio) A San Diego, FrenchBioBeach fait le pont entre la France et les US
Stéphane Richard, président et fondateur de FrenchBioBeach, présente son organisation dont la mission est d’aider les bioentrepreneurs français qui souhaitent développer leurs affaires dans la région de San Diego. Business plan, installation de filiale, … FrenchBioBeach leur apprend à se familiariser avec la culture business américaine et l’écosystème dense autour de San Diego. Créée en 2006, FrenchBioBeach travaille avec les agences françaises d’aide à l’export comme UbiFrance et les pôles de compétitivité français, et de façon plus intense avec la région PACA. L’organisation s’occupe aussi, à l’inverse, d’accompagner les entreprises américaines en France. Suivez le mode d’emploi.
Il y a une réponse pour “(audio) A San Diego, FrenchBioBeach fait le pont entre la France et les US”.
En complément des propos de Stéphane Richard, de French Biobeach, les partenaires en charge de développement économique de la région Provence-Alpes-Côte d’Azur (agences de développement économique, pôles de compétitivité des filières santé et mer, Conseil Régional et autres partenaires consulaires ou technologiques), en lien avec la filière des biotechnologies de santé axent leurs efforts, depuis plusieurs années, sur la zone de San Diego, dans le Sud californien.
Une zone particulièrement attractive sur ces sujets, du fait de sa haute spécialisation/concentration d’entreprises, réseaux, labos, universités et talents, sur ces thématiques, de sa spécificité faisant d’elle une zone non encore trop concurrentielle avec les autres régions françaises et étrangères, de son ouverture naturelle vers le reste de la Californie et les autres filières stratégiques (IT, tourisme, maritime, environnement et smartgrids, …), de son ouverture naturelle vers les marchés asiatiques, de sa proximité économique, climatique et culturelle, naturelle avec le Sud Est de la France.
French Biobeach nous offrant un relais local et un prolongement naturel de nos actions internationales, tant liées aux questions d’attractivité, que d’export et d’internationalisation de nos entreprises et/ou de coopération (scientifique, technologique, économique, politique).
Un partenaire idéalement positionné, du fait de sa double culture franco-américaine, sur la zone de San Diego, pour nous aider et conseiller sur les bons choix stratégiques liés à l’international, au bénéfice premier des entreprises et réseaux permettant des flux dans les deux sens entre nos deux régions.
Ipsen implements a new governance in the United States to prepare for the launch of Somatuline® in oncology
PARIS–(French BioBeach)–Regulatory News:
Ipsen (Euronext: IPN; ADR: IPSEY) today announced new governance in the United States, following its recently announced decision to launch Somatuline® for oncology indications. Marc de Garidel will personally oversee this projected launch. Cynthia Schwalm will join Ipsen’s US Operations to head up the Endocrinology/Oncology Business Unit as of 3 February, 2014. As of mid-August 2014, she will take over as General Manager of the US commercial affiliate.
Marc de Garidel, Chairman and CEO, Ipsen, said: “Addressing the 500 million dollars GEP- NET1 market in the US represents a key opportunity for the Group to build a long term presence in oncology. With the decision to launch Somatuline® alone, Ipsen reiterated its strong commitment to growing the US platform. In this regard, we are delighted to announce the recruitment of Cynthia Schwalm to strengthen the leadership of our US operations. Cynthia is a highly recognized executive with over 30 years of experience in oncology and in neurology and an in-depth knowledge of the US market.”
The new governance of US commercial operations will be implemented as follows:
– Marc de Garidel will act as both Chairman and CEO of the Ipsen Group and General Manager2 of the US affiliate until mid-August 2014.
– As of 3 February 2014, Cynthia Schwalm will join Ipsen as Head of the Endocrinology/Oncology Business Unit.
– As of mid-August 2014, Cynthia Schwalm will officially take up her responsibilities as US General Manager.
About Cynthia Schwalm
Cynthia Schwalm is a US citizen with over 30 years of experience in oncology and neurology. She has an in-depth knowledge of the American market. Her entire career has been spent in various pharmaceutical companies: Merz since 2012; Optimer Pharmaceuticals in 2011-2012; Eisai from 2008 to 2010; Amgen from 2003 to 2008; Johnson & Johnson from 1985 to 2003, notably in the Ortho Biotech division.
Cynthia holds an executive MBA from the Wharton School of Business, University of Pennsylvania, Philadelphia, and is a graduate of the University of Delaware, Newark.
Ipsen is a global specialty-driven pharmaceutical company with total sales exceeding €1.2 billion in 2012. Ipsen’s ambition is to become a leader in specialty healthcare solutions for targeted debilitating diseases. Its development strategy is supported by 3 franchises: neurology, endocrinology and urology-oncology. Moreover, the Group has an active policy of partnerships. Ipsen’s R&D is focused on its innovative and differentiated technological platforms, peptides and toxins. In 2012, R&D expenditure totaled close to €250 million, representing more than 20% of Group sales. The Group has close to 4,900 employees worldwide. Ipsen’s shares are traded on segment A of Euronext Paris (stock code: IPN, ISIN code: FR0010259150) and eligible to the “Service de Règlement Différé” (“SRD”). The Group is part of the SBF 120 index. Ipsen has implemented a Sponsored Level I American Depositary Receipt (ADR) program, which trade on the over-the-counter market in the United States under the symbol IPSEY. For more information on Ipsen, visit www.ipsen.com.
Forward Looking Statements
The forward-looking statements, objectives and targets contained herein are based on the Group’s management strategy, current views and assumptions. Such statements involve known and unknown risks and uncertainties that may cause actual results, performance or events to differ materially from those anticipated herein. All of the above risks could affect the Group’s future ability to achieve its financial targets, which were set assuming reasonable macroeconomic conditions based on the information available today. Use of the words “believes,” “anticipates” and “expects” and similar expressions are intended to identify forward-looking statements, including the Group’s expectations regarding future events, including regulatory filings and determinations. Moreover, the targets described in this document were prepared without taking into account external growth assumptions and potential future acquisitions, which may alter these parameters. These objectives are based on data and assumptions regarded as reasonable by the Group. These targets depend on conditions or facts likely to happen in the future, and not exclusively on historical data. Actual results may depart significantly from these targets given the occurrence of certain risks and uncertainties, notably the fact that a promising product in early development phase or clinical trial may end up never being launched on the market or reaching its commercial targets, notably for regulatory or competition reasons. The Group must face or might face competition from generic products that might translate into a loss of market share. Furthermore, the Research and Development process involves several stages each of which involves the substantial risk that the Group may fail to achieve its objectives and be forced to abandon its efforts with regards to a product in which it has invested significant sums. Therefore, the Group cannot be certain that favorable results obtained during pre-clinical trials will be confirmed subsequently during clinical trials, or that the results of clinical trials will be sufficient to demonstrate the safe and effective nature of the product concerned. There can be no guarantees a product will receive the necessary regulatory approvals or that the product will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements. Other risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the Group’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the Group’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions. The Group also depends on third parties to develop and market some of its products which could potentially generate substantial royalties; these partners could behave in such ways which could cause damage to the Group’s activities and financial results. The Group cannot be certain that its partners will fulfill their obligations. It might be unable to obtain any benefit from those agreements. A default by any of the Group’s partners could generate lower revenues than expected. Such situations could have a negative impact on the Group’s business, financial position or performance. The Group expressly disclaims any obligation or undertaking to update or revise any forward looking statements, targets or estimates contained in this press release to reflect any change in events, conditions, assumptions or circumstances on which any such statements are based, unless so required by applicable law. The Group’s business is subject to the risk factors outlined in its registration documents filed with the French Autorité des Marchés Financiers.
1 Gastro-entero-pancreatic neuroendocrine tumors
2 Subject to visa and legal considerations
For further information:
Senior Vice-President, Public Affairs and Communication
Tel.: +33 (0)1 58 33 51 16
Fax: +33 (0)1 58 33 50 58
Brigitte Le Guennec
Media and Public Relations Officer
Tel.: +33 (0)1 58 33 51 17
Fax: +33 (0)1 58 33 50 58
E-mail : firstname.lastname@example.org
Vice President, Corporate Finance, Treasury and Financial Markets
Tel.: +33 (0)1 58 33 60 08
Fax: +33 (0)1 58 33 50 63
Investor Relations Manager
Tel.: +33 (0)1 58 33 56 36
Fax: +33 (0)1 58 33 50 63
Stéphane Durant des Aulnois
Investor Relations Officer
Tel.: +33 (0)1 58 33 60 09
Fax: +33 (0)1 58 33 50 63
MEDIAN Technologies will provide imaging services for a phase II study on lung cancer
SOPHIA ANTIPOLIS, France--(BUSINESS WIRE)--January 09, 2014--
MEDIAN Technologies (Paris:ALMDT), a leading medical imaging software solutions developer and a service provider for image interpretation and management in oncology clinical trials, today announced that it has signed a contract with a San Francisco-area based biotech company. The contract amount is EUR384,000 (eq. $ 524,500).
MEDIAN Technologies will provide imaging services to support a phase II clinical trial for advanced non-small cell lung cancer. Within the framework of the study, imaging data will be acquired from 90 clinical sites, based in 12 European countries, in the US, and in Canada. Anticipated total enrollment is 440 patients with a “first patient in” forecasted May, 2014. MEDIAN will supply a set of services including clinical site qualification and training, as well as image and data collection, quality control, and storage.
“We are pleased to start 2014 supporting this important trial for a new, hypoxia-targeted therapy,” said Ciaran Cooper, Head of Business Development, Clinical Trials Imaging, North America. “Adding this new biotech client demonstrates that our imaging services bring value not only to major pharmaceutical companies, but to top biotechnology companies as well.”
About MEDIAN Technologies: MEDIAN Technologies provides advanced imaging solutions for diagnosing and monitoring cancer patients in clinical trials and in routine clinical practices. MEDIAN collaborates with institutes at the cutting edge of medical imaging, including the French National Institute for Computer Science and Control (INRIA), the University of Chicago, and the Swiss Federal Institute of Technology in Lausanne, Switzerland (EPFL). MEDIAN is present in the market through direct and indirect sales of its LMS solutions and through alliances with specialist cancer centers in Europe and the USA. MEDIAN has a strategic partnership with Canon for the development of new technologies, and a strategic partnership with the world’s largest CRO to offer integrated imaging services for clinical trials to customers worldwide.
Based in Sophia Antipolis, France, MEDIAN was founded in 2002 by Fredrik Brag (CEO), Gérard Milhiet, and Arnaud Butzbach. The company has a staff of 45, over half of whom work in R&D, and has a US-based subsidiary in the Boston area.
MEDIAN has received the label “Innovative company” by OSEO and is listed on NYSE Euronext Paris’ Alternext market (ISIN: FR0011049824, ticker: ALMDT).
For more information on MEDIAN, please visit: www.mediantechnologies.com
CONTACT: MEDIAN Technologies
Fredrik Brag, +33 4 92 90 65 82
Source : The Wall Street Journal, http://online.wsj.com/article/PR-CO-20140109-900185.html
French BioBeach supports San Diego Opera’s Life Sciences LIVE – at the Opera. Feb 21, featuring elegant networking and The Elixir of Love by Donizetti. Details and tickets: www.sdopera.com/live
PLEASE JOIN US FOR THE 18TH Annual Life Sciences LIVE at the Opera
Friday, February 21, 2014
The US Grant and San Diego Civic Theatre
About the Event
Life Sciences LIVE- at the Opera combines San Diego Opera’s world-class entertainment with the opportunity to connect with hundreds of preeminent executives, investors and research scientists from Southern California’s life sciences industry.
Pre-Opera Networking Reception: 5:00 – 6:30pm
Join the Co-Chairs and Leadership Committee at an elegant, private, pre-opera networking reception at the luxurious hotel, THE US GRANT featuring a carving stations, salads, savory hors d’oeuvres, desserts, wine, beer, coffee and soft drinks.
The Elixir of Love by Gaetano Donizetti: 7:00pm
Is it truly a magic elixir or just a bottle of cheap Bordeaux? Perhaps it doesn’t matter if it works. Nemorino desperately wants to marry the wealthy Adina, who seems out of his league. When she attracts a handsome Sergeant as her suitor, he turns in desperation to Dr. Dulcamara’s “elixir of love” in hope of winning her, spends all his money, and has to enlist to get cash for more. Overflowing with melodies and famous arias, this is the very definition of a romantic comedy. Sung in Italian with English supertitles displayed above the stage. In the San Diego Civic Theatre.
New for 2014 – immediately after the opera, join the cast and crew in the Beverly Sills Salon in the Civic Theatre to chat about the opera in a cool lounge atmosphere. Specialty cocktails, hors d’oeuvres and dessert will be available for purchase. *Optional for event-goers.
Advance Reservations Are Required!
The prices outlined below for Life Sciences LIVE – at the Opera include: Pre-Opera Networking Reception at THE US GRANT and reserved seating for The Elixir of Love on Friday, February 21, 2014.
To Purchase Tickets*
- Select Your Own Seat Buy Tickets
- Please call our Life Sciences Coordinator, Matt Kissel: (619) 533-7000, Mon-Fri, 8:30 am – 4:30 pm or email him at Matt.Kissel@sdopera.com. If you are a San Diego Opera season ticket holder and already have tickets, please contact Matt for exchanges, extra assistance, etc.
- Please note that all sales are final. No refunds or exchanges. Cast and repertoire are subject to change. Seating subject to availability. “Reception only” passes are not available for purchase – except for subscribers – as this event is designed to introduce attendees to San Diego Opera.
Section Price Balcony $145 Preferred Balcony $160 Premier Balcony $195 Dress Circle, Mezzanine $220 Orchestra $199 Preferred Dress Circle, Preferred Mezzanine, Upper Loge $255 Preferred Orchestra, Premiere Dress Circle, Premier Mezzanine, Lower Loge $300 Premiere Orchestra $315
*Please note that all sales are final. No refunds or exchanges. Cast and repertoire are subject to change. Seating subject to availability. “Reception only” passes are not available for purchase – except for subscribers – as this event is designed to introduce attendees to San Diego Opera.
Planning your visit to San Diego Opera
- Suggested attire: business and cocktail
- Run time: 2 hours and twenty minutes, including one 20 minute intermission.
- For parking and directions, click here.
- Please note – there is no late seating. Please give yourself time to make your way from THE US GRANT to the Civic Theatre (two-block walk) to ensure you make the 7:00pm curtain.
Roger Guillemin 90th Birthday Symposium – January, 13, 2014 @ The Salk Institute for Biological Studies
Hypothalamic factors: a trove for novel therapeutic and diagnostic applications
January, 13, 2014
Roger Guillemin, a distinguished Salk professor, received the Nobel Prize in 1977 for discoveries that laid the foundation for brain hormone research. Considered one of the founders of the field of neuroendocrinology, his work brought to light an entire new class of substances shown to be important for the regulation of growth, development, reproduction and responses to stress. The impact of Dr. Guillemin’s studies has been profound for a variety of diseases and disorders, including thyroid diseases, infertility, diabetes and several types of tumors.
Since his retirement from the active pursuit of laboratory research in 1989, Dr. Guillemin has shifted his long-standing expertise with computers from science to art. He uses a Macintosh computer to create images that are eventually transferred to paper and canvas. He has been instrumental in bringing art exhibits to the Salk Institute, fulfilling Jonas Salk’s vision of a facility that blends science and art.